DeepMed Research

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Idasanutlin

Generic Name: Idasanutlin

Drug Type: Small Molecule

Chemical Formula: C_₃₁H_₂₉Cl_₂F_₂N_₃O_₄

CAS Number: 1229705-06-9

Unique Ingredient Identifier: QSQ883V35U

Overview

Idasanutlin has been used in trials studying the treatment of Neoplasms, Non-Hodgkin's Lymphoma, Leukemia, Myeloid, Acute, Recurrent Plasma Cell Myeloma, and Neoplasms, Leukemia, Acute Myeloid Leukemia.

Background

Idasanutlin has been used in trials studying the treatment of Neoplasms, Non-Hodgkin's Lymphoma, Leukemia, Myeloid, Acute, Recurrent Plasma Cell Myeloma, and Neoplasms, Leukemia, Acute Myeloid Leukemia.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid Tumors

Phase 1

Withdrawn

Posted: 2023/07/19

Sponsor:St. Jude Children's ...

A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors

Phase 1

Terminated

Posted: 2019/07/23

Sponsor:Hoffmann-La Roche

A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission

Phase 1

Terminated

Posted: 2019/02/21

Sponsor:Hoffmann-La Roche

Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer

Phase 1

Terminated

Posted: 2018/06/25

Sponsor:Vanderbilt-Ingram Ca...

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)

Phase 1

Terminated

Posted: 2018/06/13

Sponsor:Hoffmann-La Roche

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Advances in Prognostication and Treatment of Polycythemia Vera with Pegylated Interferon and MDM2 Inhibition

4 years ago

Recent studies highlight the efficacy of pegylated interferon (IFN) and MDM2 inhibition in treating Polycythemia Vera (PV), a type of myeloproliferative neoplasm. Pegylated IFN, particularly IFN-α, shows promise in normalizing blood counts, reducing phlebotomy needs, and potentially inducing molecular remissions. Despite its benefits, IFN's side effects limit its use. MDM2 inhibitors, targeting the TP53 pathway, offer a novel approach, with clinical trials demonstrating reduced JAK2V617F allele burdens and improved patient outcomes. These advancements underscore the evolving landscape of PV treatment, emphasizing the need for further research to optimize therapeutic strategies.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy